Valued at USD 3.19 billion in 2024, the U.S. neurology clinical trials market is projected to reach USD 3.40 billion in 2025 and USD 6.07 billion by 2034, growing at a CAGR of 6.7% during the forecast period 2025–2034. Growth is driven by the high prevalence of neurological disorders and strong government and NIH funding support. This article examines the funding, regulatory, and infrastructure advantages that make the United States a leading location for neurology research, for B2B sponsors, CROs, and investigators.

Disease Prevalence and Funding

The U.S. faces a growing burden of neurological disorders such as Alzheimer's disease, Parkinson's disease, epilepsy, and multiple sclerosis. According to the Alzheimer's Association, 7 million people in the country have Alzheimer's disease. These conditions are becoming more common with an aging population and lifestyle-related risk factors, creating urgency to develop effective treatments and boosting demand for trials. Research institutions and pharmaceutical companies are accelerating clinical studies to meet this need as more patients seek new therapeutic options.

Strong NIH funding is the second driver. The U.S. government, particularly through the National Institutes of Health, provides substantial support for neurology research and clinical trials. Initiatives such as the BRAIN Initiative and Alzheimer's-focused programs receive billions in funding annually. NIH funding enables universities, hospitals, and biotech firms to conduct extensive trials, while grants and public-private partnerships reduce financial risk for sponsors and encourage long-term research. These efforts stimulate innovation and boost the growth of the industry in the country.

Browse Insights:

 https://www.polarismarketresearch.com/industry-analysis/us-neurology-clinical-trials-market

FDA Programs Speed Development

The U.S. Food and Drug Administration supports neurology trials through programs such as Fast Track, Breakthrough Therapy, and Orphan Drug designations. These initiatives help speed approval for drugs targeting serious or rare neurological conditions. The FDA's collaborative approach reduces time, and clear regulatory guidelines and open communication channels improve trial planning and execution. The report presents these designations as key features of the U.S. regulatory environment.

World-Class Infrastructure

The U.S. is home to world-renowned hospitals, research universities, and specialized neurology centers. Institutions such as the Mayo Clinic, Cleveland Clinic, and Johns Hopkins have dedicated neurology departments with advanced technologies and experienced investigators. The availability of centralized health data and advanced diagnostic tools improves trial accuracy and efficiency, allowing trials to be conducted faster and at a higher scientific standard, which attracts global sponsors.

Segment Insights

The phase III segment held the largest share in 2024, driven by a strong focus on late-stage drug validation. These trials involve larger patient populations and are essential for securing FDA approval, and the presence of well-established research institutions supports large, multi-center studies. By indication, the Alzheimer's disease segment held the largest share in 2024 because of its growing prevalence and unmet need; major pharmaceutical companies, biotech startups, and academic institutions are developing therapies ranging from traditional drugs to gene and antibody-based approaches, and advocacy from the Alzheimer's Association drives funding and participation.

The observational studies segment is expected to grow fastest by study design, and the CROs segment is projected to grow fastest by value chain. The report segments the market by phase, study design, indication, and value chain.

Competitive Landscape

Companies u.s. neurology clinical trials such as Biogen, Pfizer Inc., and Eisai Co., Ltd. are at the forefront of developing treatments, while IQVIA, ICON plc, Parexel, Medpace Holdings, Inc., and Syneos Health play a critical role in trial execution and recruitment. Charles River Laboratories, Thermo Fisher Scientific, and Laboratory Corporation of America Holdings provide preclinical services, laboratory testing, and diagnostics. Limited patient recruitment for rare neurological disorders and complex protocols restrains growth. Strategic collaborations, use of AI-based tools, and increasing outsourcing trends define the current competitive dynamics. In February 2025, Thermo Fisher Scientific launched a clinical registry and biorepository for Systemic Lupus Erythematosus through its CorEvitas business.

More Trending Latest Reports By Polaris Market Research:

top-5-companies-transforming-electric-vehicle-ev-parts-and-components-market-in-2025

bearings-market

understanding-the-role-of-ignition-coils-in-modern-automotive-combustion

brain-machine-interface-market

natural-stone-market

customer-experience-management-market

artificial-intelligence-in-manufacturing-market

types-of-market-research

loitering-munition-market